RESUMEN
BACKGROUND: Supplementation of nicotinamide riboside (NR) ameliorates neuropathology in animal models of ataxia telangiectasia (A-T). In humans, short-term NR supplementation showed benefits in neurological outcome. OBJECTIVES: The study aimed to investigate the safety and benefits of long-term NR supplementation in individuals with A-T. METHODS: A single-arm, open-label clinical trial was performed in individuals with A-T, receiving NR over a period of 2 years. Biomarkers and clinical examinations were used to assess safety parameters. Standardized and validated neuromotor tests were used to monitor changes in neurological symptoms. Using generalized mixed models, test results were compared to expected disease progression based on historical data. RESULTS: NAD+ concentrations increased rapidly in peripheral blood and stabilized at a higher level than baseline. NR supplementation was well tolerated for most participants. The total scores in the neuromotor test panels, as evaluated at the 18-month time point, improved for all but one participant, primarily driven by improvements in coordination subscores and eye movements. A comparison with historical data revealed that the progression of certain neuromotor symptoms was slower than anticipated. CONCLUSIONS: Long-term use of NR appears to be safe and well tolerated, and it improves motor coordination and eye movements in patients with A-T of all ages. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Ataxia Telangiectasia , Niacinamida , Animales , Humanos , Ataxia Telangiectasia/tratamiento farmacológico , Movimientos Oculares , Niacinamida/farmacología , Niacinamida/uso terapéutico , Niacinamida/análogos & derivados , Compuestos de Piridinio/uso terapéuticoRESUMEN
Glaucoma is an optic neuropathy characterized by death of retinal ganglion cells (RGCs), which leads to progressive visual field loss and may result in blindness. Currently, the only available treatment to avoid or delay progression in glaucoma patients is to decrease intraocular pressure (IOP). However, despite adequate IOP control, approximately 25% of the patients continue to progress. To delay or prevent optic nerve damage in glaucoma, two forms of vitamin B3, nicotinamide (NAM) and nicotinamide riboside (NR) are emerging as viable adjuvant therapies. These compounds are nicotinamide adenine dinucleotide (NAD) precursors. NAD is essential for proper cell functioning and is involved in several metabolic activities, including protection against reactive oxygen species, contribution to the performance of various enzymes, and maintenance of mitochondrial function. Due to its beneficial effects and to the evidence of the reduction of NAD bioavailability with aging, researchers are seeking ways to replenish the cellular NAD pool, by administrating its precursors (NAM and NR), believing that it will reduce the RGC vulnerability to external stressors, such as increased IOP. This article attempts to analyze the current knowledge regarding the use of NAM and NR for the prevention and/or treatment of glaucoma.
Asunto(s)
Glaucoma , NAD , Humanos , NAD/metabolismo , Niacinamida/uso terapéutico , Niacinamida/metabolismo , Glaucoma/tratamiento farmacológico , Glaucoma/metabolismo , Compuestos de Piridinio/uso terapéuticoRESUMEN
Alterations in cellular nicotinamide adenine dinucleotide (NAD+) levels have been observed in multiple lifestyle and age-related medical conditions. This has led to the hypothesis that dietary supplementation with NAD+ precursors, or vitamin B3s, could exert health benefits. Among the different molecules that can act as NAD+ precursors, Nicotinamide Riboside (NR) has gained most attention due to its success in alleviating and treating disease conditions at the pre-clinical level. However, the clinical outcomes for NR supplementation strategies have not yet met the expectations generated in mouse models. In this review we aim to provide a comprehensive view on NAD+ biology, what causes NAD+ deficits and the journey of NR from its discovery to its clinical development. We also discuss what are the current limitations in NR-based therapies and potential ways to overcome them. Overall, this review will not only provide tools to understand NAD+ biology and assess its changes in disease situations, but also to decide which NAD+ precursor could have the best therapeutic potential.
Asunto(s)
NAD , Niacinamida , Animales , Modelos Animales de Enfermedad , Ratones , Niacinamida/análogos & derivados , Niacinamida/farmacología , Niacinamida/uso terapéutico , Compuestos de Piridinio/uso terapéuticoRESUMEN
We conducted a double-blinded phase I clinical trial to establish whether nicotinamide adenine dinucleotide (NAD) replenishment therapy, via oral intake of nicotinamide riboside (NR), is safe, augments cerebral NAD levels, and impacts cerebral metabolism in Parkinson's disease (PD). Thirty newly diagnosed, treatment-naive patients received 1,000 mg NR or placebo for 30 days. NR treatment was well tolerated and led to a significant, but variable, increase in cerebral NAD levels-measured by 31phosphorous magnetic resonance spectroscopy-and related metabolites in the cerebrospinal fluid. NR recipients showing increased brain NAD levels exhibited altered cerebral metabolism, measured by 18fluoro-deoxyglucose positron emission tomography, and this was associated with mild clinical improvement. NR augmented the NAD metabolome and induced transcriptional upregulation of processes related to mitochondrial, lysosomal, and proteasomal function in blood cells and/or skeletal muscle. Furthermore, NR decreased the levels of inflammatory cytokines in serum and cerebrospinal fluid. Our findings nominate NR as a potential neuroprotective therapy for PD, warranting further investigation in larger trials.
Asunto(s)
NAD , Enfermedad de Parkinson , Suplementos Dietéticos , Humanos , NAD/metabolismo , Niacinamida/análogos & derivados , Niacinamida/farmacología , Niacinamida/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Compuestos de Piridinio/uso terapéuticoRESUMEN
Supplementation with precursors of NAD has been shown to prevent and reverse insulin resistance, mitochondrial dysfunction, and liver damage in mouse models of diet-induced obesity. We asked whether the beneficial effects of supplementation with the NAD precursor nicotinamide riboside (NR) are dependent on mouse strain. We compared the effects of NR supplementation on whole-body energy metabolism and mitochondrial function in mildly obese C57BL/6N and C57BL/6J mice, two commonly used strains to investigate metabolism. Male C57BL/6N and C57BL/6J mice were fed a high-fat diet (HFD) or standard chow with or without NR supplementation for 8 weeks. Body and organ weights, glucose tolerance, and metabolic parameters as well as mitochondrial O2 flux in liver and muscle fibers were assessed. We found that NR supplementation had no influence on body or organ weight, glucose metabolism or hepatic lipid accumulation, energy expenditure, or metabolic flexibility but increased mitochondrial respiration in soleus muscle in both mouse strains. Strain-dependent differences were detected for body and fat depot weight, fasting blood glucose, hepatic lipid accumulation, and energy expenditure. We conclude that, in mild obesity, NR supplementation does not alter metabolic phenotype in two commonly used laboratory mouse strains.
Asunto(s)
Metabolismo Energético/efectos de los fármacos , Niacinamida/análogos & derivados , Obesidad/tratamiento farmacológico , Compuestos de Piridinio/uso terapéutico , Animales , Respiración de la Célula/efectos de los fármacos , Dieta Alta en Grasa , Modelos Animales de Enfermedad , Evaluación de Medicamentos , Intolerancia a la Glucosa/prevención & control , Metabolismo de los Lípidos/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones Endogámicos C57BL , Músculo Esquelético/metabolismo , Niacinamida/uso terapéutico , Obesidad/metabolismoRESUMEN
BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder stemming from a loss of functional dystrophin. Current therapeutic options for DMD are limited, as small molecule modalities remain largely unable to decrease the incidence or mitigate the consequences of repetitive mechanical insults to the muscle during eccentric contractions (ECCs). METHODS: Using a metabolomics-based approach, we observed distinct and transient molecular phenotypes in muscles of dystrophin-deficient MDX mice subjected to ECCs. Among the most chronically depleted metabolites was nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor suggested to protect muscle from structural and metabolic degeneration over time. We tested whether the MDX muscle NAD pool can be expanded for therapeutic benefit using two complementary small molecule strategies: provision of a biosynthetic precursor, nicotinamide riboside, or specific inhibition of the NAD-degrading ADP-ribosyl cyclase, CD38. RESULTS: Administering a novel, potent, and orally available CD38 antagonist to MDX mice successfully reverted a majority of the muscle metabolome toward the wildtype state, with a pronounced impact on intermediates of the pentose phosphate pathway, while supplementing nicotinamide riboside did not significantly affect the molecular phenotype of the muscle. However, neither strategy sustainably increased the bulk tissue NAD pool, lessened muscle damage markers, nor improved maximal hindlimb strength following repeated rounds of eccentric challenge and recovery. CONCLUSIONS: In the absence of dystrophin, eccentric injury contributes to chronic intramuscular NAD depletion with broad pleiotropic effects on the molecular phenotype of the tissue. These molecular consequences can be more effectively overcome by inhibiting the enzymatic activity of CD38 than by supplementing nicotinamide riboside. However, we found no evidence that either small molecule strategy is sufficient to restore muscle contractile function or confer protection from eccentric injury, undermining the modulation of NAD metabolism as a therapeutic approach for DMD.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Metaboloma , Músculo Esquelético/metabolismo , Distrofia Muscular de Duchenne/tratamiento farmacológico , NAD/metabolismo , Niacinamida/análogos & derivados , Compuestos de Piridinio/farmacología , ADP-Ribosil Ciclasa 1/antagonistas & inhibidores , Animales , Distrofina/deficiencia , Inhibidores Enzimáticos/uso terapéutico , Masculino , Glicoproteínas de Membrana/antagonistas & inhibidores , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos mdx , Contracción Muscular , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiología , Distrofia Muscular de Duchenne/genética , Distrofia Muscular de Duchenne/metabolismo , Niacinamida/farmacología , Niacinamida/uso terapéutico , Compuestos de Piridinio/uso terapéuticoRESUMEN
INTRODUCTION: The high world prevalence of rhinosinusitis (RS) initiates the ways of a favorable search for effective and safe medicines for its pathogenetic treatment. The important part of this process is the choice of the most comfortable dosage form, which will enhance therapeutic compliance and ensure the appropriate medicine efficacy and safety. AIM: To substantiate the efficacy of a new nasal spray with anti-inflammatory properties containing Enisamium Iodide (EI) at a concentration of 10 mg/mL by histomorphological study of the nasal cavity and paranasal sinuses mucosal in rabbits with experimental rhinosinusitis (ERS). METHODS: EI (nasal spray) was a test object. Sinupret® was a reference drug. ERS was induced in rabbits on the first day of the study by tamponade of the right half of the nasal cavity under general anesthesia. The study was performed using 24 rabbits (4 groups, 6 rabbits in each group). The histomorphological examination was performed on the 25th day of the study by the standard light microscopy methods. RESULTS: The histomorphological examination of EI 10 mg/mL (nasal spray) impact on RS in rabbits, which administered during 10 days intranasally, revealed the significant therapeutic effect presented by reduced inflammation signs in the epithelium of the nasal cavities and paranasal sinuses mucosal. Besides, the EI impact was not inferior to the reference drug Sinupret® in tablets. The study of the pharmacological properties of the EI (nasal spray) on ERS showed the high rate of onset of EI actions when used intranasally which was superior to the rate of actions of the reference drug Sinupret® (tablets) administered intragastrically. CONCLUSION: The EI (nasal spray) is a promising drug for a pathogenetic therapy of acute RS, which demands further pre-clinical and clinical studies aiming to substantiate its implementation to the clinical practice.
Asunto(s)
Antiinflamatorios/uso terapéutico , Cavidad Nasal/anatomía & histología , Cavidad Nasal/efectos de los fármacos , Rociadores Nasales , Extractos Vegetales/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Rinitis/tratamiento farmacológico , Sinusitis/tratamiento farmacológico , Administración Intranasal , Animales , Antiinflamatorios/administración & dosificación , Humanos , Modelos Animales , ConejosRESUMEN
OBJECTIVE: Nicotinamide riboside (NR) has been proved to protect the hearing. To achieve animal models of temporary threshold shift (TTS) and permanent threshold shift (PTS) respectively, evaluate the dynamic change of ribbon synapse before and after NR administration. METHODS: Mice were divided into control group, noise exposure (NE) group and NR group. The noise was exposed to NE and NR group, and NR was injected before noise exposure. Auditory brainstem response (ABR), ribbon synapse count and cochlear morphology were tested, as well as the concentration of hydrogen peroxide (H2O2) and ATP. RESULTS: Ribbon synapse count decrease with the intensity of noise exposure, and the cochlear morphology remains stable during TTS and was damaged during PTS. NR promotes the oxidation resistance to protect the synapse and the inner ear morphology. CONCLUSION: Our findings suggest that TTS mice are more vulnerable to noise, and NR can promote the recovery of the synapse count to protect the animals' hearing.
Asunto(s)
Estimulación Acústica/efectos adversos , Células Ciliadas Auditivas Internas/fisiología , Pérdida Auditiva Provocada por Ruido/prevención & control , Niacinamida/análogos & derivados , Compuestos de Piridinio/uso terapéutico , Recuperación de la Función/fisiología , Sinapsis/fisiología , Animales , Células Ciliadas Auditivas Internas/efectos de los fármacos , Células Ciliadas Auditivas Internas/patología , Pérdida Auditiva Provocada por Ruido/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Niacinamida/farmacología , Niacinamida/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Compuestos de Piridinio/farmacología , Sinapsis/efectos de los fármacos , Sinapsis/patologíaRESUMEN
The influence of three newly developed bispyridinium antinicotinic compounds (the non-oximes MB408, MB442 and MB444) on the therapeutic efficacy of a standard antidotal treatment (atropine in combination with an oxime) of acute poisoning by the organophosphorus nerve agents tabun and soman was studied in mice. The therapeutic efficacy of atropine in combination with an oxime with or without one of the bispyridinium non-oximes was evaluated by determination of the LD50 values of the nerve agents and measurement of the survival time after supralethal poisoning. Addition of all the tested non-oximes increased significantly the therapeutic efficacy of atropine in combination with an oxime against tabun poisoning. They also positively influenced the number of surviving mice 6 hr after supralethal poisoning with tabun. However, they were only slightly effective for the treatment of soman poisoning. The benefit of the tested bispyridinium non-oximes was dose-dependent. To conclude, the addition of bispyridinium non-oximes to the standard antidotal treatment of acute poisoning with tabun was beneficial regardless of the chosen non-oxime, but only slightly beneficial in the case of soman poisoning.
Asunto(s)
Antídotos/uso terapéutico , Agentes Nerviosos/envenenamiento , Agonistas Nicotínicos/farmacología , Intoxicación por Organofosfatos/tratamiento farmacológico , Compuestos de Piridinio/uso terapéutico , Animales , Antídotos/síntesis química , Antídotos/farmacología , Atropina/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Humanos , Dosificación Letal Mediana , Masculino , Ratones , Agonistas Nicotínicos/síntesis química , Intoxicación por Organofosfatos/etiología , Organofosfatos/toxicidad , Oximas/farmacología , Compuestos de Piridinio/síntesis química , Compuestos de Piridinio/farmacología , Soman/envenenamiento , Resultado del TratamientoRESUMEN
Photodynamic therapy (PDT) is known to alter the expression of various genes in treated cells. This prompted us to examine the activity of genes encoding two important enzymes in sphingolipid (SL) metabolism, dihydroceramide desaturase (DES) and sphingosine kinase (SPHK), in mouse SCCVII tumor cells treated by PDT using either the porphyrin-based photosensitizer Photofrin or silicon phthalocyanine Pc4. The results revealed that PDT induced an upregulation in the expression of two major isoforms of both genes (DES1 and DES2 as well as SPHK1 and SPHK2). While the changes were generally moderate (2-3-fold gains), the increase in DES2 expression was more pronounced and it was much greater with Photofrin-PDT than with Pc4-PDT (over 23-fold vs. less than 5-fold). Combining either Photofrin-PDT or Pc4-PDT with the cationic C16-ceramide LCL30 (20mg/kg i.p.) for treatment of subcutaneously growing SCCVII tumors rendered important differences in the therapy outcome. Photofrin-PDT, used at a dose that attained good initial response but no tumor cures, produced 50% cures when combined with a single LCL30 treatment. In contrast, the same LCL30 treatment combined with Pc4-PDT had no significant effect on tumor response. The optimal timing of LCL30 injection was immediately after Photofrin-PDT. The therapeutic benefit was lost when LCL30 was given in two 20mg/kg injections encompassing intervals before and after PDT. LCL85, the cationic B13 ceramide analogue and SL-modulating agent, also increased cure rates of Photofrin-PDT treated tumors, but the therapeutic benefit was less pronounced than with LCL30. These results with LCL30 and LCL85, and our previous findings for LCL29 (another SL analogue), assert the potential of SLs for use as adjuvants to augment the efficacy of PDT-mediated tumor destruction.
Asunto(s)
Carcinoma de Células Escamosas/tratamiento farmacológico , Ceramidas/farmacología , Fotoquimioterapia , Propanolaminas/farmacología , Compuestos de Piridinio/farmacología , Esfingosina/análogos & derivados , Animales , Carcinoma de Células Escamosas/genética , Ceramidas/uso terapéutico , Quimioterapia Adyuvante , Ratones , Oxidorreductasas/genética , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Propanolaminas/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Esfingosina/farmacología , Esfingosina/uso terapéutico , Resultado del Tratamiento , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/efectos de la radiaciónRESUMEN
BACKGROUND: SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. PROCEDURES: SCH 727965 was tested against the PPTP in vitro panel using 96 hours exposure at concentrations ranging from 0.1 nM to 1.0 µM. It was tested against the PPTP in vivo panels at a dose of 40 mg/kg administered intraperitoneally twice weekly for 2 weeks and repeated at Day 21 with a total observation period of 6 weeks. RESULTS: The median IC(50) value for the cell lines was 7.5 nM, with less than fourfold range between the minimum (3.4 nM) and maximum (11.2 nM) IC(50) values. SCH 727965 demonstrated an activity pattern consistent with cytotoxicity for most of the cell lines. Forty-three xenograft models were studied and SCH 727965 induced significant delays in event free survival distribution compared to control in 23 of 36 (64%) evaluable solid tumor xenografts and in 3 of 7 ALL xenografts. SCH 727965 did not induce objective responses in the solid tumor panels and the best response observed was stable disease for one osteosarcoma xenograft. In the leukemia panel, there were two objective responses with a complete response observed in a single xenograft. CONCLUSIONS: SCH 727965 shows an interesting pattern of activity suggesting its potential applicability against selected childhood cancers, particularly leukemias.
Asunto(s)
Antineoplásicos/uso terapéutico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Evaluación Preclínica de Medicamentos , Neoplasias Experimentales/tratamiento farmacológico , Compuestos de Piridinio/uso terapéutico , Animales , Antineoplásicos/farmacocinética , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacocinética , Línea Celular Tumoral , Niño , Óxidos N-Cíclicos , Supervivencia sin Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Indolizinas , Ratones , Ratones Endogámicos C57BL , Ratones Desnudos , Ratones SCID , Trasplante de Neoplasias , Compuestos de Piridinio/farmacocinética , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Eradication of tumours by photodynamic therapy (PDT) is accompanied by marked changes in local sphingolipid (SL) engagement. Because of the heterogeneity of cellular composition, analysis of tumour tissue homogenates to quantify SL species is inadequate for evaluating their levels in parenchymal cancer cell population. By staining tumour-derived single cell suspensions with antibodies specific to ceramide and sphingosine 1-phosphate (S1P) followed by flow cytometry, we were able to document changes in the levels of these two key SLs in cancer cells and tumour-associated macrophages (TAMs) of mouse SCCVII tumours following PDT. The results confirm previously obtained indications that tumour treatment by PDT induces a marked rise in ceramide levels in cancer cells within these lesions. Cancer cells from PDT-treated SCCVII tumours undergoing apoptosis were found to have much higher ceramide levels and substantially lower S1P levels than their viable counterparts. Compared to cancer cells, considerably higher ceramide and S1P levels were consistently found in TAMs. Treatment of SCCVII tumour-bearing mice with ceramide analog LCL29 induced a rise in ceramide levels in TAMs but not in cancer cells. When combined with PDT, LCL29 treatment produced a further increase in ceramide levels in TAMs while having no evident impact on ceramide content in cancer cells within same tumours. The results highlight SLs as important participants in tumour response to PDT and potential adjuvant therapeutic targets to PDT.
Asunto(s)
Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/metabolismo , Ceramidas/metabolismo , Lisofosfolípidos/metabolismo , Fotoquimioterapia , Esfingosina/análogos & derivados , Animales , Apoptosis/efectos de los fármacos , Carcinoma de Células Escamosas/patología , Ceramidas/uso terapéutico , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/metabolismo , Neoplasias de Cabeza y Cuello/patología , Indoles/uso terapéutico , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Macrófagos/patología , Mesoporfirinas/uso terapéutico , Ratones , Ratones Endogámicos C3H , Compuestos de Organosilicio/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Esfingosina/metabolismoRESUMEN
BACKGROUND AND OBJECTIVES: C6-ceramide analog LCL29 was recently shown to improve the cure rates of mouse tumors treated by photodynamic therapy (PDT), but the mechanism underlying the therapeutic gain remains unclear. Since LCL29 is a pro-apoptotic agent, the main objective of the present study was to determine how LCL29 affects cancer cell apoptosis in PDT-treated tumors. STUDY DESIGN/MATERIALS AND METHODS: Mice bearing SCCVII tumors (syngeneic squamous cell carcinomas) were treated by PDT with photosensitizer Foscan. Adjuvant LCL29 treatment (40 mg/kg) was 24 hours before PDT. The tumors were excised 3 hours after PDT, disaggregated into single cell suspensions that were stained for flow cytometry to detect apoptosis-related events in cancer cells (caspase activation, loss of mitochondrial transmembrane potential, and intracellular calcium). In addition, phagocytic activity in tumor-associated macrophages was assessed by phalloidin staining. RESULTS: While 5-10% apoptotic cancer cells were found in tumors treated by PDT or LCL29 alone, close to 40% of such cells were found in tumors treated by LCL29 combined with PDT. Mitochondrial depolarization was detected in PDT, LCL29, and LCL29 + PDT groups, reaching similar values in all groups. Intracellular calcium release triggered by PDT was more pronounced when PDT was combined with LCL29. Macrophage phagocytic activity, negatively affected by PDT, was stimulated by adjuvant LCL29. CONCLUSIONS: Combining LCL29 treatment with PDT can enhance intracellular calcium release in cancer cells and strongly amplify their apoptosis.
Asunto(s)
Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Carcinoma de Células Escamosas/tratamiento farmacológico , Ceramidas/uso terapéutico , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Fotoquimioterapia , Compuestos de Piridinio/uso terapéutico , Animales , Antineoplásicos/farmacología , Calcio/metabolismo , Ceramidas/farmacología , Quimioterapia Adyuvante , Citometría de Flujo , Macrófagos/efectos de los fármacos , Mesoporfirinas/uso terapéutico , Ratones , Ratones Endogámicos C3H , Mitocondrias/efectos de los fármacos , Fagocitosis/efectos de los fármacos , Fármacos Fotosensibilizantes/uso terapéutico , Compuestos de Piridinio/farmacologíaRESUMEN
Tabun belongs to the most toxic nerve agents. Its mechanism of action is based on acetylcholinesterase (AChE) inhibition at the peripheral and central nervous systems. Therapeutic countermeasures comprise administration of atropine with cholinesterase reactivators able to reactivate the inhibited enzyme. Reactivation of AChE is determined mostly biochemically without specification of different brain structures. Histochemical determination allows a fine search for different structures but is performed mostly without quantitative evaluation. In rats intoxicated with tabun and treated with a combination of atropine and HI-6, obidoxime, or new oxime K048, AChE activities in different brain structures were determined using biochemical and quantitative histochemical methods. Inhibition of AChE following untreated tabun intoxication was different in the various brain structures, having the highest degree in the frontal cortex and reticular formation and lowest in the basal ganglia and substantia nigra. Treatment resulted in an increase of AChE activity detected by both methods. The highest increase was observed in the frontal cortex. This reactivation was increased in the order HI-6 < K048 < obidoxime; however, this order was not uniform for all brain parts studied. A correlation between AChE activity detected by histochemical and biochemical methods was demonstrated. The results suggest that for the mechanism of action of the nerve agent tabun, reactivation in various parts of the brain is not of the same physiological importance. AChE activity in the pontomedullar area and frontal cortex seems to be the most important for the therapeutic effect of the reactivators. HI-6 was not a good reactivator for the treatment of tabun intoxication.
Asunto(s)
Encéfalo/efectos de los fármacos , Reactivadores de la Colinesterasa/farmacología , Cloruro de Obidoxima/farmacología , Organofosfatos/antagonistas & inhibidores , Organofosfatos/toxicidad , Oximas/farmacología , Compuestos de Piridinio/farmacología , Acetilcolinesterasa/metabolismo , Animales , Atropina , Encéfalo/enzimología , Encéfalo/patología , Sustancias para la Guerra Química/toxicidad , Inhibidores de la Colinesterasa/administración & dosificación , Inhibidores de la Colinesterasa/toxicidad , Reactivadores de la Colinesterasa/administración & dosificación , Reactivadores de la Colinesterasa/uso terapéutico , Femenino , Lóbulo Frontal/efectos de los fármacos , Lóbulo Frontal/enzimología , Lóbulo Frontal/patología , Proteínas Ligadas a GPI/metabolismo , Dosificación Letal Mediana , Cloruro de Obidoxima/administración & dosificación , Cloruro de Obidoxima/uso terapéutico , Especificidad de Órganos , Organofosfatos/administración & dosificación , Oximas/administración & dosificación , Oximas/uso terapéutico , Compuestos de Piridinio/administración & dosificación , Compuestos de Piridinio/uso terapéutico , Ratas , Ratas Wistar , Formación Reticular/efectos de los fármacos , Formación Reticular/enzimología , Formación Reticular/patologíaRESUMEN
MHP-133 is one of a novel series of compounds designed to target multiple brain substrates expected to have synergistic actions in the treatment of cognitive and neurodegenerative disorders such as Alzheimer's disease. The strategy was to develop compounds with multiple targets relevant for enhancing cognition and memory, but avoiding the serious side effects attributed to high potency cholinergic agonists. MHP-133 was shown to interact with subtypes of cholinergic, serotonergic, and imidazoline receptors and to weakly inhibit acetylcholinesterase activity. In vitro, the drug enhanced nerve growth factor (TrkA) receptor expression; it prevented excitotoxicity in a hippocampal slice preparation; and increased the secretion of soluble (non-toxic) amyloid precursor protein. MHP-133 also enhanced cognitive performance by rats and by non-human primate in tasks designed to assess working memory. The results of this study are consistent with the potential use of MHP-133 in the treatment of neurodegenerative disorders such as Alzheimer's disease.
Asunto(s)
Sistema Nervioso Central/efectos de los fármacos , Cognición/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Compuestos de Piridinio/farmacología , Precursor de Proteína beta-Amiloide/metabolismo , Animales , Sistema Nervioso Central/anatomía & histología , Sistema Nervioso Central/metabolismo , Antagonistas Colinérgicos/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Macaca mulatta , Masculino , Aprendizaje por Laberinto , Estructura Molecular , Enfermedades Neurodegenerativas/tratamiento farmacológico , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/metabolismo , Fármacos Neuroprotectores/uso terapéutico , Células PC12 , Compuestos de Piridinio/química , Compuestos de Piridinio/metabolismo , Compuestos de Piridinio/uso terapéutico , Ratas , Ratas Sprague-Dawley , Receptor trkA/metabolismo , Receptores de Superficie Celular/metabolismoRESUMEN
The mechanism of intoxication with organophosphorus compounds, including highly toxic nerve agents and less toxic pesticides, is based on the formation of irreversibly inhibited acetylcholinesterase, which causes cumulation of neuromediator acetylcholine in synaptic clefts and subsequent overstimulation of cholinergic receptors, that is followed by a generalized cholinergic crisis. Nerve agent poisoning is conventionally treated using a combination of a cholinolytic (atropine mostly) to counteract the accumulation of acetylcholine and acetylcholinesterase reactivators (pralidoxime or obidoxime) to reactivate inhibited acetylcholinesterase. In this study of cyclosarin poisoning treatment, oximes of different chemical structures (obidoxime, HI-6, BI-6, and HS-6) were tested in vitro on rat brain acetylcholinesterase (enzyme source: rat brain homogenate), and afterwards, they were tested in vivo in equimolar doses, in mice and rats. The HI-6 oxime appeared to be the most effective oxime in vitro and in vivo.
Asunto(s)
Inhibidores de la Colinesterasa/toxicidad , Reactivadores de la Colinesterasa/farmacología , Compuestos Organofosforados/toxicidad , Oximas/farmacología , Compuestos de Piridinio/farmacología , Animales , Antídotos/farmacología , Antídotos/uso terapéutico , Atropina/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Reactivadores de la Colinesterasa/uso terapéutico , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/toxicidad , Femenino , Técnicas In Vitro , Cinética , Dosificación Letal Mediana , Ratones , Antagonistas Muscarínicos/uso terapéutico , Cloruro de Obidoxima/farmacología , Cloruro de Obidoxima/uso terapéutico , Oximas/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Ratas , Ratas WistarRESUMEN
OBJECTIVE: In this study, we evaluated the time course of the alterations in left ventricular (LV) dimensions, LV wall thickness, and LV systolic function in rats with endotoxemia by using echocardiography as well as myocardial histopathologic assessments. Our second goal was to examine whether pretreatment with a platelet-activating factor (PAF) antagonist would ameliorate the lipopolysaccharide (LPS)-induced cardiovascular collapse during the early phase. DESIGN: A prospective, controlled, in vivo animal laboratory study. SETTING: Research laboratory at a university. SUBJECTS: Male, Wistar rats (8-9 wks old; n = 83). INTERVENTIONS: In pentobarbital-anesthetized rats, the right carotid artery was cannulated to measure the arterial blood pressure and to sample blood. The right jugular vein also was catheterized for the administration of drugs. LPS (2 mg/kg) derived from Klebsiella pneumoniae or physiologic saline was administered in the presence or absence of pretreatment with TCV-309, a specific potent PAF antagonist. Echocardiographic studies were performed with an 8- to 13-MHz transducer. MEASUREMENTS AND MAIN RESULTS: LPS administration immediately induced progressive hypotension. The maximal hypotensive response was observed at 10 mins after LPS infusion with mean arterial pressure decreasing from 119 +/- 2 to 56 +/- 3 mm Hg (p < .001). LV end-diastolic internal dimensions decreased from 6.4 +/- 0.1 to 3.1 +/- 0.1 mm (p < .001) at 30 mins after LPS and remained significantly reduced compared with control rats. LV end-systolic dimensions also decreased dramatically from 3.5 +/- 0.2 to 0.5 +/- 0.1 mm (p < .001) at 30 mins after LPS and remained significantly reduced throughout the experiment. LV fractional shortening increased from 45 +/- 1% to 84 +/- 2% (p < .001) at 30 mins after LPS and remained elevated compared with control rats. LV wall thickness increased strikingly from 15 mins until 2 hrs after LPS infusion. Pathologic studies demonstrated marked congestion of capillaries and mild edema in the LV myocardium. The hematocrit increased after the administration of LPS. LPS markedly increased sympathetic tone as demonstrated by the elevation of plasma concentrations of epinephrine and norepinephrine. There was no elevation of concentrations of nitrite and nitrate. Pretreatment with TCV-309, a specific potent PAF antagonist, reduced LPS-induced hypotension and attenuated LV functional and structural changes. TCV-309 administration reduced the LPS-induced adrenergic activation and hemoconcentration. CONCLUSIONS: The hypotension that occurred during the initial phase of LPS-induced shock was accompanied by LV functional and structural alterations. The marked increase in LV wall thickness can be ascribed to the congestion of capillaries and edema in the LV myocardium. Pretreatment with a PAF antagonist reduced LPS-induced alterations. PAF may play a pivotal role during the initial phase of LPS-induced cardiovascular responses.
Asunto(s)
Modelos Animales de Enfermedad , Endotoxemia/complicaciones , Endotoxemia/inmunología , Isoquinolinas/uso terapéutico , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/inmunología , Klebsiella pneumoniae , Lipopolisacáridos , Factor de Activación Plaquetaria/antagonistas & inhibidores , Factor de Activación Plaquetaria/inmunología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Compuestos de Piridinio/uso terapéutico , Tetrahidroisoquinolinas , Disfunción Ventricular Izquierda/microbiología , Disfunción Ventricular Izquierda/prevención & control , Animales , Evaluación Preclínica de Medicamentos , Ecocardiografía , Electrocardiografía , Endotoxemia/metabolismo , Epinefrina/sangre , Hematócrito , Isoquinolinas/inmunología , Infecciones por Klebsiella/metabolismo , Masculino , Nitratos/sangre , Nitritos/sangre , Norepinefrina/sangre , Inhibidores de Agregación Plaquetaria/inmunología , Estudios Prospectivos , Compuestos de Piridinio/inmunología , Ratas , Ratas Wistar , Sístole , Factores de Tiempo , Disfunción Ventricular Izquierda/diagnósticoRESUMEN
UNLABELLED: OBJECTIVESz: To study the clinical and urodynamic effects of oral distigmine bromide (distigmine) by using pressure-flow studies in patients who were persistently poor voiders after transurethral resection of the prostate. METHODS: The study included 14 poor voiders after transurethral resection of the prostate who were 50 years old or older. Their poor voiding conditions were characterized by a mean International Prostate Symptom Score of 18.9 or a mean quality-of-life index of 4.6 and a mean maximum flow rate of 8.9 mL/s. All patients underwent symptomatic and urodynamic investigations before and after 4 weeks of daily treatment with 15 mg oral distigmine. RESULTS: In the baseline pressure-flow studies, all patients had weak detrusor contractility as demonstrated by Schäfer's diagram and the maximum Watts factor but did not have bladder outlet obstruction. They had symptomatic improvements after oral distigmine treatment, with the International Prostate Symptom Score reduced to a mean of less than 10 and the quality-of-life index reduced to a mean of less than 3. In the urodynamic investigations, the maximum flow rate improved significantly to a mean of more than 12 mL/s in parallel with a significant increase in the maximum Watts factor. Detrusor contractility according to Schäfer's diagram also tended to improve after oral distigmine treatment. However, no significant changes were found in any of the parameters of bladder outlet obstruction. CONCLUSIONS: Poor voiders after transurethral resection of the prostate who have weak detrusor contractility without bladder outlet obstruction may benefit clinically from treatment with distigmine because of its efficacy in increasing detrusor contractility without enhancing bladder outlet obstruction.
Asunto(s)
Inhibidores de la Colinesterasa/uso terapéutico , Contracción Muscular/efectos de los fármacos , Compuestos de Piridinio/uso terapéutico , Resección Transuretral de la Próstata/efectos adversos , Trastornos Urinarios/tratamiento farmacológico , Trastornos Urinarios/etiología , Urodinámica/efectos de los fármacos , Administración Oral , Anciano , Anciano de 80 o más Años , Humanos , Masculino , Persona de Mediana Edad , Resección Transuretral de la Próstata/métodos , Trastornos Urinarios/fisiopatologíaRESUMEN
In experiment on anesthetized dogs and cats in was shown that the new water-soluble copolymer initiated depressive reaction characteristic for beta-adrenomimetics. This effect was levelled with the help of non-selective adrenoblockator--propranololum. In experiment on dogs the preliminary treatment with propranololum decreased the therapeutic antiradiation efficiency of the copolymer from 68.4 to 8.3%.
Asunto(s)
Hemodinámica/efectos de los fármacos , Polivinilos/farmacología , Compuestos de Piridinio/farmacología , Protectores contra Radiación/farmacología , Receptores Adrenérgicos beta/efectos de los fármacos , Antagonistas Adrenérgicos beta/farmacología , Animales , Gatos , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Rayos gamma , Hemodinámica/efectos de la radiación , Polivinilos/uso terapéutico , Propranolol/farmacología , Compuestos de Piridinio/uso terapéutico , Traumatismos Experimentales por Radiación/tratamiento farmacológico , Traumatismos Experimentales por Radiación/mortalidad , Protectores contra Radiación/uso terapéutico , Receptores Adrenérgicos beta/efectos de la radiación , Solubilidad , Factores de TiempoRESUMEN
The results of in vitro and in vivo experiments were used to compare the capacity of bispiridinium oximes to modulate the presynaptic secretion of acetylcholine and to demonstrate the protective activity against organophosphate intoxication during combined application with various M-cholinolytics. It is suggested that bispiridinium oximes combined with M-cholinolytics can play a corrective role in eliminating the adverse presynaptic effect of a cholinolytic, thus lowering the severity of intoxication.